Advanced Breast Carcinoma

Oncology
4
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Knight Therapeutics
Knight TherapeuticsQC - Montréal
2 programs
1
1
AbemaciclibPhase 2Small Molecule1 trial
AlectinibPhase 1Small Molecule1 trial
Active Trials
NCT05238831Withdrawn0Est. May 2026
NCT06630325Active Not Recruiting30Est. Jun 2033
Celldex Therapeutics
1 program
1
ONT-10, Varlilumab combinationPhase 11 trial
Active Trials
NCT02270372Completed22Est. Jun 2016
Pfizer
PfizerNEW YORK, NY
1 program
1
ONT-10, Varlilumab combinationPhase 1

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Knight TherapeuticsAbemaciclib
Knight TherapeuticsAlectinib
Celldex TherapeuticsONT-10, Varlilumab combination

Clinical Trials (3)

Total enrollment: 52 patients across 3 trials

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Start: Jun 2025Est. completion: Jun 203330 patients
Phase 2Active Not Recruiting

SMMART Adaptive Clinical Treatment (ACT) Trial

Start: Jan 2023Est. completion: May 20260
Phase 1Withdrawn
NCT02270372Celldex TherapeuticsONT-10, Varlilumab combination

Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer

Start: Nov 2014Est. completion: Jun 201622 patients
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

Small Molecule is the dominant modality (100% of programs)
3 companies competing in this space